Table 1.
Characteristics of the included studies which employed PSMA radioligands in gliomas.
| First Author and Year | Type | Country | N. Patients | Tracer | Histopathological Subtype (N. Patients) |
Clinical Setting (N. Patients) |
Analysed Lesions | Comparator |
|---|---|---|---|---|---|---|---|---|
| Sasikumar 2017 [29] | Not reported | India | 6 | 68Ga-PSMA-11 (I) | 6 high-grade | Initial diagnosis or restaging | 6 | MRI 18F-FDG PET/CT |
| Sasikumar 2018 [30] | Prospective | India | 15 | 68Ga-PSMA-11 (I) | 1 low-grade; 14 high-grade |
Initial diagnosis or restaging | 15 | MRI |
| Verma 2019 [31] | Not reported | India | 10 | 68Ga-PSMA-11 (I) | 3 low-grade; 7 high-grade |
Initial diagnosis | 10 | MRI 18F-FDG PET/CT |
| Akgun 2020 [32] | Prospective | Turkey | 35 | 68Ga-PSMA-11 (I) | 14 low-grade; 21 high-grade |
Initial diagnosis | 35 | MRI |
| Kunikowska 2020 [33] | Not reported | Poland | 15 | 68Ga-PSMA-11 (I) | 15 high-grade | Restaging | 15 | MRI |
| Kumar 2021 [34] | Prospective | India | 33 | 68Ga-PSMA-11 (I) | 33 high-grade | Restaging | 33 | MRI |
| Liu 2021 [35] | Retrospective | China | 30 | 68Ga-PSMA-617(I) | 14 low-grade; 16 high-grade |
Initial diagnosis | 30 | MRI 18F-FDG PET/CT |
| Kunikowska 2022 [36] | Not reported | Poland | 34 | 68Ga-PSMA-11 (I) | 34 high-grade | Restaging | 34 | MRI |
PET: positron emission tomography, CT: computed tomography, MRI: magnetic resonance imaging, PSMA: prostate-specific membrane antigen, FDG: fluorodeoxyglucose, I: imaging.